Heparin-associated antiplatelet antibodies increase morbidity and mortality in hemodialysis patients  by Mureebe, L. et al.
equine-derived estrogen are at an increased risk of VTE events. Certain
categories of patients, however, appear to be at prohibitive risk.
Risk factors and recurrence rate of primary deep vein thrombosis of the
upper extremities
Martinelli I, Vattaglioli T, Bucciarelli P, et al. Circulation 2004;110:566-70.
Conclusion: The risk of upper extremity deep vein thrombosis
(UEDVT) increases in patients with inherited thrombophilia. Oral contra-
ceptives increase the risk of UEDVT thrombosis only in patients with
inherited thrombophilia. The recurrence rate of primary UEDVT is low but
tends to be higher in patients with thrombophilia.
Summary: The authors studied 115 cases of primary UEDVT and 797
healthy controls. Patients with UEDVT and controls were investigated for
thrombophilia secondary to prothrombin G20210A, factor V Leiden, anti-
thrombin, protein C, protein S deficiency, and hyperhomocysteinemia.
Transient risk factors for venous thrombosis were also recorded. Median
follow-up was 5.1 years.
The factor V Leiden-adjusted odds ratio (OR) for UEDVT was 6.2
(95% confidence interval [CI], 2.5 to 15.7) and the OR for prothrombin
G20210A was 5.0 (95% CI, 2.0 to 12.2). For other anticoagulant protein
deficiencies, the OR for UEDVT was 4.9 (95% CI, 1.1 to 22.0). There was
no association between oral contraceptives and hyperhomocysteinemia and
UEDVT. There were additive effects of oral contraceptives, factor V Leiden,
and prothrombin G20210A. In women taking oral contraceptives who also
had abnormalities of factor V Leiden or prothrombin G20210A, the OR for
UEDVT increased to 13.6 (95% CI, 2.7 to 67.3). Recurrence of UEDVT
was 4.4% patient-years in patients with thrombophilia and 1.6% patient-years
in patients without thrombophilia. Strenuous muscular effort of the arms
was present in only 25% of the patients with primary UEDVT.
Comment:Obviously, patients with primary UEDVT should be inves-
tigated for inherited thrombophilia. However, the relatively low risk of
recurrence of UEDVT, even in patients with thrombophilia, does not
support prolonged or life-long anticoagulation in all patients with UEDVT,
regardless of thrombophilia status. Nevertheless, knowledge of the throm-
bophilia status may be important, especially in women of reproductive age.
Variation in rates of appropriate and inappropriate carotid endarterec-
tomy for stroke prevention in four Canadian provinces
Kennedy J, Quan H, Ghali WA, et al. CMAJ 2004;171:455-9.
Conclusion: There is both overuse and underuse of carotid endarter-
ectomy that varies by region. High rates of performance of carotid endar-
terectomy are associated with a lower rate of appropriate performance of the
operation for both surgeons and hospitals.
Summary: The authors identified all carotid endarterectomies per-
formed in the Canadian provinces of Saskatchewan, Alberta, Manitoba, and
British Columbia from January 2000 to December 2001. Chart review and
expert assessment were used to determine the proportion of procedures that
were appropriate, inappropriate, or of uncertain appropriateness according
to the RAND-University of California, Los Angeles (UCLA) appropriate-
ness method. The data were analyzed to determine variations and rates of
performance of carotid endarterectomy and whether variation was due to
differences in surgical volume, surgical specialty, or type of hospital.
The RAND-UCLA appropriateness method determined that 1,656
(52.3%) of the 3,167 carotid endarterectomies were performed for appro-
priate indications. The proportion of appropriate procedures was 78.2% in
Saskatchewan, 58.7% in Alberta, 49.1% in Manitoba, and 46.0% in British
Columbia (P .001 across provinces). The rate of appropriate performance
of procedures per 100,000 of population varied from 16.2 in Saskatchewan
to 44.3 in Manitoba (P  .001 across provinces). Carotid endarterectomy
was more likely to be appropriate when performed by a neurosurgeon
compared with other surgeons (74.4% vs 49.4% P .001), when performed
by surgeons doing fewer than 31 procedures over 2 years compared with
surgeons doing greater than 31 procedures over 2 years (70.1% vs 49.5%, P
 .001), and when performed in hospitals doing fewer than 135 procedures
yearly compared with hospitals doing more than 135 procedures yearly
(63.4% vs 49.1%, P  .001). The RAND-UCLA appropriateness method
determined that 10.3% of procedures were done for inappropriate reasons.
Comment: There is a complex relationship between uncertainty, over-
use, and underuse in the performance of any surgical procedure. It is clearly
possible to have both overuse and underuse of a procedure. It is, however,
somewhat disconcerting to note that the appropriateness of carotid endar-
terectomy in this study was inversely related to surgeon and hospital volume,
suggesting that surgeons and hospitals who perform high volumes of carotid
surgery do so because of a higher volume of inappropriate operations.
Endovascular aortic repair or minimal incisional aortic surgery: Which
procedure to choose for treatment of high-risk aneurysms?
Tefera G, Carr SC, Turnipseed WD. Surgery 2004;136:748-53.
Conclusion: Endovascular aneurysm repair (EVAR) and minimal in-
cision aortic surgery (MIAS) give comparable results for the treatment of
high-risk patients with aneurysms.
Summary: The authors investigated the comparable efficacy of EVAR
and MIAS in the treatment of high-risk patients with infrarenal aortic
aneurysms. EVAR was performed using standard techniques. MIAS was
performed through a small midline incision (8 to 12 cm) with intra-
abdominal visceral retraction. A hand-sewn aortic anastomosis was per-
formed.
This was a retrospective review of patients treated with EVAR or MIAS
between 2000 and 2002. Patients were thought to be high-risk based on age
80 years, creatinine 3.0mg/dL, recent myocardial infarction, history of
congestive heart failure, severe pulmonary disease, hostile abdomen, or
morbid obesity (BMI30). Exclusionary criteria for EVAR were an aneu-
rysm neck 1.5 cm in length or 26 mm in diameter, the presence of
densely calcified iliac arteries (6 mm), or a serum creatinine3.0 mg/dL.
Patients were excluded from MIAS for the presence of perirenal abdominal
aortic aneurysm, morbid obesity, and aneurysm diameter 10 cm. Data
analyzed included demographics, morbidity, mortality, and duration of stay.
Of the 84 patients in the study, 61 were treated with EVAR and 23
were treated with MIAS. The average age was 72 years for MIAS and 74
years for EVAR. The average aneurysm size was 6 cm in both groups.
American Society for Anesthesiologists score was 3.0 for MIAS patients and
3.1 for EVAR patients. Two risk factors were present in 52% of EVAR
patients and in 30% of MIAS patients. Three risk factors were present in 20%
of EVAR patients and in 30% of MIAS patients. Two deaths (3%) occurred
in the EVAR group and one (4%) in theMIAS group. Average operative stay
was 5.1 days for both groups. Thirty-day morbidity was 18% for EVAR and
17% for MIAS.
Comment:TheWisconsin group has acquired considerable experience
with both EVAR and MIAS. The current study suggests EVAR and MIAS
are comparable in the high-risk aneurysm population. The authors, however,
continue to dance around performance of a randomized trial in their
institution. They appear to have both the expertise and the patients to
perform such a trial, and it is probably time to do so.
Heparin-associated antiplatelet antibodies increase morbidity and
mortality in hemodialysis patients
Mureebe L, Coats RD, Silliman WR, et al. Surgery 2004;136:848-53.
Conclusion: Morbidity and mortality are elevated in hemodialysis
patients with heparin-associated antiplatelet antibodies (HAAb). Dialysis
patients with HAAb should be considered for alternative anticoagulation
during hemodialysis.
Summary: Patients on hemodialysis are frequently exposed to heparin.
Patient groups with frequent heparin exposure developHAAb at a high rate.
This study sought to define the prevalence of HAAb in hemodialysis patients
and to evaluate the potential affects of HAAb in hemodialysis patients. The
authors identified all patients undergoing hemodialysis at their institution,
3.7% of whom tested positive for HAAb. These patients were reviewed and
compared with a control group consisting of randomly selected hemodialysis
patients who tested negative for HAAb. Thromboembolic and hemorrhagic
complications were higher in HAAb-positive patients compared with con-
trol patients (60% vs 8.7%, P  .05). Mortality directly related to thrombo-
embolic or hemorrhagic complications was also higher in HAAb-positive
patients (28.6% vs 4.35%, P  .05).
Comment: The primary thrombotic morbidity in the dialysis patients
with HAAb in this study was thromboses of permanent dialysis access,
including both fistulas and grafts. The data suggest that patients with
dialysis-access thrombosis should be investigated for HAAb, and if positive,
alternative forms of anticoagulation should be considered during hemodial-
ysis.
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